A medical case report published in Medicine (Baltimore) documents a 12-year-old boy who developed acute noncardiogenic pulmonary edema after receiving neostigmine. The complication occurred during the recovery phase of general anesthesia, highlighting specific respiratory risks associated with the drug’s administration in perioperative settings.
Clinical Observations of Pulmonary Edema in Pediatric Patients
The administration of neostigmine during the recovery period of general anesthesia has been linked to the development of acute noncardiogenic pulmonary edema (ANPE). A case study published on May 25, 2018, in the journal Medicine (Baltimore), detailed the experience of a 12-year-old boy suffering from dry gangrene. During the patient’s recovery from general anesthesia, the administration of neostigmine resulted in the onset of ANPE.
The research was conducted by a team at the China-Japan Union Hospital of Jilin University, including Wenjing Zhang, PhD; Cong Ning, MD; Guoqing Zhao, PhD; and Zhenbo Su, PhD. The study identifies ANPE as a rare but significant complication that typically occurs during the perioperative period, specifically before or after extubation as a patient recovers from general anesthesia.
Respiratory Risks in Post-Transplant Management
Beyond pediatric cases, neostigmine use presents documented complications for adult patients, particularly those with complex pulmonary histories. In a report featured in the Society of Critical Care Anesthesiologists (SOCCA) newsletter, Volume 34, Issue 1, clinicians detailed the treatment of a 68-year-old male who had undergone bilateral lung transplantation.
The patient presented with a significant medical history, including hypertension, asthma, obstructive sleep apnea (OSA), prostate cancer following a prostatectomy, atrial fibrillation, and progressive interstitial pneumonia with autoimmune features. Following the transplant, the patient developed ileus, which was treated with a series of intravenous neostigmine boluses.
The administration of the drug led to a measurable decline in respiratory stability. According to the report by Tyler Beattie, MD, Douglas R. Adams, MD, and Gozde Demiralp, MD, the treatment resulted in increased pulmonary secretions and oxygen requirements
.
Pharmacological Side Effects of Acetylcholinesterase Inhibition
Neostigmine functions as a reversible acetylcholinesterase inhibitor and acts as a parasympathomimetic drug. While it has an on-label use for reversing neuromuscular paralytics, it is also used off-label to treat acute colonic pseudo-obstruction and critical illness associated ileus.
The physiological effects of the drug can extend to several critical systems. Clinical data indicates that neostigmine is associated with side effects such as bradycardia and asystole. The drug is also linked to specific pulmonary complications, including bronchospasm and an increase in pulmonary secretions.
Medical professionals monitoring patients during the perioperative period must account for these potential reactions. The transition from general anesthesia to spontaneous breathing—specifically during the extubation process—remains a high-risk window for these respiratory events.
